<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837235</url>
  </required_header>
  <id_info>
    <org_study_id>HM005PS1S04</org_study_id>
    <nct_id>NCT04837235</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects</brief_title>
  <acronym>Hemay005</acronym>
  <official_title>Clinical Study of Safety, Tolerability, and Pharmacokinetics of Hemay005 Tablets in Single and Multiple Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Hemay Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Hemay Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the&#xD;
      treatment of psoriasis. There were 3 dose cohorts (75mg, 90mg, 105mg) with 12 healthy&#xD;
      subjects in each cohorts (6 males and 6 females). This study includes an 11-day Screening&#xD;
      Period, a 1-day single dose and 7-days multiple doses Treatment Period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AEs), related AEs and serious AEs (SAEs)</measure>
    <time_frame>From Day 1 to Day 11</time_frame>
    <description>All subjects who receive the drug will be analyzed for safety, and the safety evaluation will refer to CTCAE 5.0 standard.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>75mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/tablet. Five tablets (75mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/tablet. Six tablets (90mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>105mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/tablet. Seven tablets (105mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemay005</intervention_name>
    <description>oral</description>
    <arm_group_label>105mg group</arm_group_label>
    <arm_group_label>75mg group</arm_group_label>
    <arm_group_label>90mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. healthy subjects aged 18 to 60 years, The ratio of male to female is 1:1&#xD;
&#xD;
          2. male Bodyweight（BW）≥ 50kg, female Bodyweight（BW）≥ 45kg, Body mass index (BMI) in 18-28&#xD;
             (including upper and lower limit of the range);&#xD;
&#xD;
          3. All male subjects must agree and commit to the use of a reliable contraceptive&#xD;
             regimen(including vasoligation, abstinence, using a condom) for the duration of the&#xD;
             study(from screening until 6 months after the last dose), Female participants with a&#xD;
             negative pregnancy test (serum) at both the screening visit and at Day-1, Female&#xD;
             subjects and female partners of male subjects must agree and commit to the use of a&#xD;
             reliable contraceptive regimen ( oral contraceptive medications or non-oral&#xD;
             contraceptive medications) for the duration of the study(from screening until 6 months&#xD;
             after the last dose);&#xD;
&#xD;
          4. Ability to understand and be willing to sign a written informed consent before study&#xD;
             entry;&#xD;
&#xD;
          5. Subjects would have good communication with the investigator and could comply with&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of clinically severe gastrointestinal, hepatic, renal, cardiovascular,&#xD;
             dermatological, immunological, respiratory, endocrine, oncological, neurological,&#xD;
             metabolic, psychiatric disease or haematological disorders;&#xD;
&#xD;
          2. Have a known history of hypersensitivity to any medicine or food, or allergy to the&#xD;
             test article or any of the excipient of the test article;&#xD;
&#xD;
          3. Those who have or are suffering from gastrointestinal, liver and kidney diseases that&#xD;
             affect drug absorption or metabolism&#xD;
&#xD;
          4. A history of chronic infection (ie, tuberculosis);&#xD;
&#xD;
          5. A medical history of any clinically significant medical disease or surgery within 4&#xD;
             weeks of the screening&#xD;
&#xD;
          6. Clinically significant laboratory abnormal results at screening or prior to the first&#xD;
             dose of study drug;&#xD;
&#xD;
          7. Clinically significant abnormal 12-lead ECG or vital signs&#xD;
&#xD;
          8. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B&#xD;
             virus surface antigen, hepatitis C virus antibody or Treponema pallidum antibody at&#xD;
             screening;&#xD;
&#xD;
          9. Within 1 year before study enrollment of frequent alcohol consumption, defined by&#xD;
             average intake of greater than 14 units of alcohol per week (1 unit = 360 mL beer or&#xD;
             45 mL of spirits with 40% alcohol content, or 150 mL wine), Participants who are&#xD;
             unable to abstain from smoking during the study or quitting smoking for less than 3&#xD;
             months;&#xD;
&#xD;
         10. Positive urine screen for drug and cigarettes, positive breath test for alcohol;&#xD;
&#xD;
         11. Subjects who use soft drugs (ie marijuana )within 3 months of the screening and entire&#xD;
             study duration or hard drugs (ie cocaine, phencyclidine ) within 1 year of the&#xD;
             screening and entire study duration;&#xD;
&#xD;
         12. Dietary habits or food intolerances which will interfere with the requirements for&#xD;
             participants to consume a standardised diet whilst confined to the clinical unit;&#xD;
&#xD;
         13. Participants who eat special food (Including grapefruit and/or Xanthine diet) for 14&#xD;
             days prior to dosing or any caffeine containing food or drinks, i.e. chocolate for 48&#xD;
             hours prior to dosing or drinking alcohol for 24 hours prior to dosing and not will&#xD;
             stop to intake above food and drinks;&#xD;
&#xD;
         14. Use of any drug that inhibits or induces hepatic metabolism of drugs within 30 days of&#xD;
             planned study drug administration and entire study duration (e.g. inducers:&#xD;
             barbiturates, carbamazepine, rifampicin, phenytoin, glucocorticoid and omeprazole;&#xD;
             inhibitors-SSRI（Selective serotonin reuptake inhibitors） antidepressants, cimetidine,&#xD;
             diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil,&#xD;
             fluoroquinolones and antihistamines);&#xD;
&#xD;
         15. Participant who received any medicine within 14 days of the initial dose of study&#xD;
             drug;&#xD;
&#xD;
         16. Have received other clinical trials treatment within 3 months prior to study;&#xD;
&#xD;
         17. Participants who have donated of blood (&gt;400 mL) within 4 weeks of the study, or plan&#xD;
             to donate of blood during of the study and 4 weeks after the study;&#xD;
&#xD;
         18. Subjects cannot complete the study due to other reasons or by the investigator's&#xD;
             judgment;&#xD;
&#xD;
         19. Pregnancy or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemay005</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

